Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
- 1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
Abstract
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV outcomes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and everolimus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of baseline. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated rejection, or antibody-mediated rejection occurred during letermovir prophylaxis; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.
Related
- Higher tissue concentrations of cefuroxime achieved with preoperative stand-alone intraosseous regional prophylaxis in robotic-assisted total knee arthroplasty: a randomized controlled trial.
- Clinical Course and Discontinuation of Olanzapine Long-Acting Injectable: A Retrospective Case Series Including a Case of Post-Injection Delirium/Sedation Syndrome
- Cytochrome P450 2D6 Metabolizer Phenotype Is Associated With Metoprolol Pharmacodynamics But Not With Metoprolol Discontinuation: A Retrospective Cohort Study in the All of Us Research Program
- Comparison between mono-tacrolimus and mono-prednisone in the treatment of ocular myasthenia gravis: a retrospective, observational cohort study
- Empirical Antibiotic Initiation for Suspected Early-Onset Neonatal Infection in the Setting of Maternal GBS Screening and Intrapartum Antibiotic Prophylaxis: A Single-Center Retrospective Cohort Study
BibTeX
@article{uchida2026changes,
title = {{Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study}},
author = {Junji Uchida and Shunji Nishide and Yuji Takeyama and Taiyo Otoshi and Minoru Kato and Takeshi Yamasaki and Tomoaki Iwai and Toshihide Naganuma and Katsuyuki Kuratsukuri},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207875},
url = {https://www.mdpi.com/2077-0383/15/20/7875},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
AU - Junji Uchida
AU - Shunji Nishide
AU - Yuji Takeyama
AU - Taiyo Otoshi
AU - Minoru Kato
AU - Takeshi Yamasaki
AU - Tomoaki Iwai
AU - Toshihide Naganuma
AU - Katsuyuki Kuratsukuri
PY - 2026
DA - 2026/10/13
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207875
UR - https://www.mdpi.com/2077-0383/15/20/7875
AB - Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV outcomes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and everolimus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of baseline. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated rejection, or antibody-mediated rejection occurred during letermovir prophylaxis; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.
SN - 2077-0383
ER -